[VIRTUAL] Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study

[VIRTUAL] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

[VIRTUAL] Niraparib in patients with newly diagnosed advanced ovarian brcam cancer: a post hoc analysis of the prima/engot-ov26/gog-3012 trial

[VIRTUAL] Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): a multicenter, single-arm, phase 2 trial

[VIRTUAL] Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial

[VIRTUAL] Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study

[VIRTUAL] Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. Baseline Results of a Randomized Clinical Trial

[VIRTUAL] Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial

[VIRTUAL] Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: prima/ENGOT-OV26/GOG-3012 study

[VIRTUAL] Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab

[VIRTUAL] ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)

[VIRTUAL] Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients

[VIRTUAL] Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-OV50/GOG-329/INNOVATE-3